

A

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION TRANSMITTAL

Docket No: 1543.004/12169US04

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith for filing is the patent application of

Inventor(s): Martha Jo Whitehouse (a/k/a M.J. Whitehouse)

Title: "Angiogenically Effective Unit Dose of FGF-2 and Method of Use"

1. Type of Application

This new application is for a

☒ utility patent.


☐ design patent.

2. Application Papers Enclosed

- | | |
|-------------------------------------|--|
| 1 | Title Page |
| 49 | Pages of Specification (excluding Claims, Abstract & Drawings) |
| 7 | Page(s) of Claims |
| 1 | Page(s) of Abstract |
| 5 | Sheet(s) of Drawings (Figs. 1A, 1B, 2, 3 and 4) |
| <input checked="" type="checkbox"/> | Formal |
| <input type="checkbox"/> | Informal |
| <input checked="" type="checkbox"/> | <u>3</u> Sheets of Sequence Listing |

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this Patent Application Transmittal and the documents referred to as enclosed therewith are being deposited with the United States Postal Service on **August 27, 1999**, in an envelope addressed to: Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231 utilizing the "Express Mail Post Office to Addressee" service of the United States Postal Service under Mailing Label No. EL026004755US



Adnan Muslimovic



09385114, 082799

3. **Statement Under 37 FR § 1.821**

In accordance with 37 CFR § 1.821, the undersigned attorney hereby states that the contents of the enclosed paper and computer readable copies of the SEQUENCE LISTING are the same.

4. **Declaration or Oath**

Enclosed

Executed by (check all applicable boxes)

Inventor(s)

☐ Legal representative of inventor(s)
(37 CFR 1.42 or 1.43)

☐ Joint inventor or person showing a proprietary interest on behalf of inventor who refused to sign or cannot be reached

☐ The petition required by 37 CFR 1.47 and the statement required by 37 CFR 1.47 are enclosed.
See Item 5D below for fee.

☒ Not enclosed – the undersigned attorney or agent is authorized to file this application on behalf of the applicant(s). An executed declaration will follow.

5. **Additional Papers Enclosed**

☐ Preliminary Amendment

☐ Information Disclosure Statement

☐ Declaration of Biological Deposit

☒ Computer readable copy of sequence listing containing nucleotide and/or amino acid sequence

☐ Verified statement(s) claiming small entity status under 37 CFR 1.9 and 1.27

☐ Associate Power of Attorney

☐ Verified translation of a non-English patent application

☐ An assignment of the invention

☐ Certified copy(ies) of application(s):

6. Claim of Priority

COUNTRY	APPLICATION NO.	FILED
U.S.	60/145,743	September 03, 1998
U.S.	60/104,103	October 13, 1998
U.S.	60/104,102	October 13, 1998

from which priority under 35 USC 120 is claimed.

7. Filing Fee Calculation (37 CFR 1.16)

A. ☒ Utility Application

CLAIMS AS FILED - INCLUDING PRELIMINARY AMENDMENT (IF ANY)						
			SMALL ENTITY		OTHER THAN A SMALL ENTITY	
	NO. FILED	NO. EXTRA	RATE	FEE	RATE	FEE
BASIC FEE						\$760.00
TOTAL	34	14	X 9 =	\$	X 18 =	\$252.00
INDEP.	5	=2	X 39 =	\$	X 78 =	\$156.00
<input type="checkbox"/> First Presentation of Multiple Dependent Claim			+ 130 =	\$	+ 260 =	\$
Filing Fee:				\$	OR	1,168.00

B. ☐ Design Application (\$155.00/\$310.00) Filing Fee: \$ _____

C. ☐ Plant Application (\$248.00/\$480.00) Filing Fee: \$ _____

D. Other Fees

☐ Recording Assignment [Fee -- \$40.00 per assignment] \$ _____

☐ Petition fee for filing by other than all the inventors or person on behalf of the inventor where inventor refused to sign or cannot be reached [Fee -- \$130.00] \$ _____

☐ Other \$ _____

Total Fees Enclosed \$1,168.00

8. **Method of Payment of Fees**

- ☒ Enclosed check in the amount of: \$ 1,168.00
☐ Charge Deposit Account No. 13-0017 in the amount of: \$ _____

A copy of this Transmittal is enclosed.

- ☐ Not enclosed

8. **Deposit Account and Refund Authorization**

The Commissioner is hereby authorized to charge any deficiency in the amount enclosed or any additional fees which may be required during the pendency of this application under 37 CFR 1.16 or 37 CFR 1.17 or under other applicable rules (except payment of issue fees), to Deposit Account No. 13-0017. **A copy of this Transmittal is enclosed.**

Please refund any overpayment to McAndrews, Held & Malloy, Ltd. at the address below.

Please direct all future communications to:

**JOSEPH H. GUTH, ESQ.
CHIRON CORPORATION
4560 HORTON STREET
P.O. BOX 8097
INTELLECTUAL PROPERTY R-440
EMERYVILLE, CALIFORNIA 94662-8097**

Respectfully submitted,

McANDREWS, HELD & MALLOY, LTD.

By: 

Donald J. Pochopien
Registration No. 32,167
500 West Madison Street
34th Floor
Chicago, Illinois 60661
(312) 707-8889

Date: August 27, 1999

j:\open\DJP\Chiron\USPTO\1543004 Patent Appln. Trl. Doc